Last updated: August 14, 2026
Dimethyl fumarate has shifted from a high-growth branded multiple sclerosis product to a mature, genericized market. Biogen's Tecfidera remains the largest commercial reference, but U.S. generic entry after the invalidation of a key patent materially reduced branded revenue. The market now divides into low-cost generic dimethyl fumarate, differentiated fumarate products such as Biogen's Vumerity, and competing oral and high-efficacy multiple sclerosis therapies.
What is the current market position of dimethyl fumarate?
Dimethyl fumarate is an oral disease-modifying therapy approved for relapsing forms of multiple sclerosis. Tecfidera was approved by the U.S. Food and Drug Administration in March 2013 and became one of the leading oral multiple sclerosis drugs because it combined twice-daily oral dosing with broad neurologic efficacy and a lower administration burden than injectable products (FDA, 2013).
The commercial market has three principal segments:
| Segment |
Representative product |
Commercial status |
Primary competitive factor |
| Originator dimethyl fumarate |
Tecfidera, Biogen |
Mature branded product |
Physician familiarity and established clinical data |
| Generic dimethyl fumarate |
Multiple ANDA-approved products |
Active U.S. competition |
Price and formulary access |
| Next-generation fumarate |
Vumerity, diroximel fumarate |
Branded, differentiated product |
Gastrointestinal tolerability and conversion from Tecfidera |
Dimethyl fumarate competes with oral therapies including teriflunomide, fingolimod, ozanimod, ponesimod and cladribine, as well as injectable interferons and glatiramer acetate. High-efficacy monoclonal antibodies, including ocrelizumab, natalizumab and ofatumumab, exert additional pressure in patients and treatment settings where relapse control is prioritized over convenience or low monitoring burden.
How has the financial trajectory of Tecfidera changed?
Tecfidera revenue peaked before generic competition and then declined sharply after U.S. generic entry. Biogen's product revenue history shows the typical pattern for a small-molecule blockbuster: rapid adoption, peak sales, patent litigation, generic launch and continuing price erosion.
| Period |
Tecfidera commercial position |
Approximate Biogen product-revenue trend |
| 2013-2015 |
Launch and rapid penetration of oral MS market |
Strong annual growth |
| 2016-2019 |
Mature blockbuster |
Approximately $4 billion-plus at peak worldwide sales |
| 2020 |
U.S. generic entry and loss of effective market exclusivity |
Sharp decline |
| 2021-2022 |
Generic substitution expands |
Approximately $1.3 billion to $1.7 billion range |
| 2023-2024 |
Mature branded and international erosion |
Continued decline toward roughly $1 billion or below |
Biogen reported Tecfidera revenue of approximately $4.4 billion in 2019. Revenue fell to approximately $2.4 billion in 2020 and continued declining in subsequent years as generic dimethyl fumarate gained formulary placement and pharmacy substitution. Exact reported totals vary by accounting period and geographic presentation, but the direction is clear: Tecfidera lost more than half of its peak revenue within roughly two years of generic entry (Biogen, 2020, 2021, 2022, 2023).
The financial impact extended beyond volume. Generic competition affected:
- Average selling price.
- Rebates paid to commercial insurers and pharmacy benefit managers.
- Net revenue per prescription.
- U.S. patient-support economics.
- Physician willingness to initiate branded Tecfidera.
- International reference pricing.
Biogen retained some branded demand because of physician familiarity, patient-support programs and established safety experience. Those factors did not prevent substantial substitution once generic products became available.
When did dimethyl fumarate lose exclusivity?
Dimethyl fumarate lost meaningful U.S. market exclusivity in 2020, although the timing resulted from patent litigation rather than the simple expiration of FDA regulatory exclusivity.
FDA regulatory exclusivity
Tecfidera received five years of new chemical entity exclusivity under the Hatch-Waxman Act. That period generally ran from the March 2013 approval date until March 2018. NCE exclusivity blocked the submission of ANDAs during the exclusivity period but did not itself prevent patent challenges or later generic approval once the statutory period ended (FDA, 2024a).
The key commercial protection came from patents listed in the FDA Orange Book, rather than from NCE exclusivity.
Patent litigation and effective loss of protection
Biogen asserted U.S. Patent No. 8,399,514 against generic applicants. The patent covered a specific dimethyl fumarate dosing regimen and was listed in connection with Tecfidera. The U.S. District Court for the District of Delaware found the patent invalid for obviousness, and the U.S. Court of Appeals for the Federal Circuit affirmed the judgment in 2020.
The Federal Circuit decision removed the principal barrier to generic approval. Several generic manufacturers launched after the litigation outcome, including products marketed by companies such as Mylan, Amneal, Zydus and other ANDA sponsors. The result was an earlier generic entry than Biogen's commercial strategy had anticipated (Biogen v. Mylan, 2020).
What patents protect Tecfidera and generic dimethyl fumarate?
The principal U.S. patent dispute centered on formulation and dosing claims rather than on a broad, durable composition-of-matter patent for the active ingredient.
| Patent or protection category |
Commercial relevance |
Status or outcome |
| U.S. Patent No. 6,509,376 |
Earlier fumaric-acid-ester intellectual property |
Expired or no longer a practical barrier to generic entry |
| U.S. Patent No. 8,399,514 |
Dosing regimen involving dimethyl fumarate |
Invalidated for obviousness; Federal Circuit affirmed |
| Orange Book-listed secondary patents |
Potential formulation, dosage or method protection |
Impact depends on claim scope and litigation outcome |
| Pediatric exclusivity |
Possible six-month extension for qualifying listed patents |
Requires FDA-recognized pediatric completion and applicable patent timing |
| Foreign patents |
Country-specific formulation and method protection |
Varies materially by jurisdiction |
The patent estate was commercially weaker than the revenue profile suggested. Dimethyl fumarate is a known small molecule, and the active ingredient itself did not provide a durable, late-expiring composition patent comparable to the protection available for many newer chemical entities. The more relevant defenses involved dosing, delayed-release delivery, capsule technology and method-of-use claims.
The Federal Circuit's decision is especially important because it treated the claimed dosing regimen as obvious in view of the prior art. That analysis reduced the value of relying on routine dose-selection patents to protect a major branded product (U.S. Court of Appeals for the Federal Circuit, 2020).
What formulation patents protect dimethyl fumarate products?
The commercially important formulation concept is delayed-release delivery. Tecfidera is supplied as delayed-release capsules, which are intended to manage gastrointestinal exposure and support twice-daily administration.
Formulation protection can target:
- Enteric coating systems.
- Capsule composition.
- Particle size and active-ingredient distribution.
- Stability and impurity control.
- Release profiles.
- Dose strength and capsule architecture.
- Manufacturing processes that preserve fumarate stability.
These claims may delay individual generic applicants, but they rarely create a broad market barrier if the FDA determines that an ANDA product is therapeutically equivalent and does not infringe enforceable claims. Generic manufacturers can also design around narrow coating or manufacturing claims.
What is the Orange Book status of Tecfidera?
Tecfidera has historically relied on Orange Book-listed patents to support patent certifications and litigation against ANDA applicants. The most important listed patent, U.S. Patent No. 8,399,514, was invalidated. Once the key patent barrier was removed, FDA approval of generic ANDAs became possible.
Orange Book status has three practical effects:
- It determines which patents generic applicants must address in an ANDA certification.
- It can trigger a 30-month stay when the innovator files timely patent litigation.
- It defines the scope of the patent dispute, but it does not guarantee that listed patents survive litigation.
The current commercial significance of any remaining Orange Book listings is narrower than the pre-2020 estate. Generic competition already exists, and a later-expiring secondary patent would need to cover a commercially unavoidable feature of the product to restore meaningful exclusivity.
Which companies are challenging or competing with Tecfidera?
The U.S. generic market includes multiple ANDA sponsors and manufacturers. Generic competition has involved large multinational companies and specialty generic manufacturers, including Mylan/Viatris, Amneal, Zydus and other approved applicants.
The competitive structure is fragmented:
| Competitor group |
Examples |
Effect on dimethyl fumarate economics |
| Generic manufacturers |
Viatris/Mylan, Amneal, Zydus and other ANDA sponsors |
Lower price and rapid substitution |
| Biogen fumarate products |
Tecfidera and Vumerity |
Retains branded prescriber and patient segments |
| Oral MS therapies |
Aubagio, Gilenya, Zeposia, Ponvory, Mavenclad |
Compete for treatment initiation and switching |
| High-efficacy biologics |
Ocrevus, Tysabri, Kesimpta |
Pull patients toward stronger disease control |
| Injectable therapies |
Avonex, Rebif, Copaxone and others |
Remain options where cost or familiarity matters |
The largest threat to generic dimethyl fumarate is not another generic. It is therapeutic substitution. Neurologists may choose a high-efficacy biologic for patients with active or aggressive disease, while patients with tolerability concerns may move to another oral therapy.
How does Vumerity compare with Tecfidera?
Vumerity contains diroximel fumarate, a prodrug that converts to monomethyl fumarate, the same active metabolite produced by dimethyl fumarate. Biogen positioned Vumerity as a fumarate alternative with a potentially improved gastrointestinal tolerability profile.
| Factor |
Tecfidera |
Vumerity |
| Active pharmaceutical ingredient |
Dimethyl fumarate |
Diroximel fumarate |
| Administration |
Twice daily |
Twice daily |
| Market position |
Mature and genericized |
Branded follow-on product |
| Main value proposition |
Established efficacy and familiarity |
Potentially improved GI tolerability |
| Patent position |
Key patent invalidation enabled generics |
Separate, later-expiring product estate |
| Commercial role |
Legacy franchise |
Lifecycle-management product |
Vumerity has partly absorbed Biogen's fumarate franchise after generic Tecfidera entry. Its ability to protect revenue depends on whether payers accept a branded premium and whether patients experience meaningful tolerability or adherence benefits.
Vumerity does not eliminate generic substitution risk. Its patent estate must protect the specific prodrug, formulation or use claims, and the product remains exposed to future ANDA challenges. Its commercial trajectory is stronger than Tecfidera's only if the tolerability proposition supports persistent net pricing and switching from low-cost generic dimethyl fumarate.
What generic entry risks exist for dimethyl fumarate?
Generic entry risk is high in the United States and other major markets where patent barriers have fallen. The main risks are commercial rather than regulatory.
Price erosion
Multiple generic suppliers typically create rapid price competition. The first approved generic may achieve attractive margins, but later entrants pressure acquisition costs and reimbursement rates.
Formulary substitution
Pharmacy-level substitution and payer-preferred generic placement can move market share without a physician changing the prescription. This is particularly important for chronic multiple sclerosis therapy, where treatment persistence and refill economics drive recurring revenue.
Therapeutic switching
Patients may switch from fumarates to other oral agents or biologics. Branded follow-on products must demonstrate a clear clinical or tolerability advantage to resist this movement.
Manufacturing and quality risk
Dimethyl fumarate is chemically accessible, but commercial manufacture still requires:
- Control of fumarate-related impurities.
- Stable delayed-release coating.
- Consistent capsule fill and dissolution.
- Validated analytical methods.
- Compliance with FDA current good manufacturing practice requirements.
Manufacturing barriers are therefore moderate, not prohibitive. They can delay individual suppliers but are unlikely to preserve monopoly pricing once several manufacturers have validated products.
What is the FDA regulatory status of dimethyl fumarate?
The FDA has approved dimethyl fumarate delayed-release capsules for relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. The product carries safety-monitoring requirements associated with lymphopenia, infections, liver injury, hypersensitivity and progressive multifocal leukoencephalopathy risk (FDA, 2013).
The regulatory framework supports generic approval through an ANDA when the applicant demonstrates pharmaceutical equivalence, bioequivalence and compliance with applicable quality standards. Generic applicants do not repeat the full clinical development program required for the original NDA.
There is no biosimilar pathway for dimethyl fumarate because it is a chemically synthesized small molecule. Biosimilar risk is therefore not applicable. The relevant pathway is Hatch-Waxman ANDA competition.
What is the international market outlook for dimethyl fumarate?
International erosion has been slower and more uneven than U.S. erosion because patent expiry, reimbursement systems and generic-substitution rules differ by country.
Europe
European pricing pressure depends on national health technology assessment, tendering, reference pricing and local patent status. Generic and hybrid applications can enter at different times across European markets. Biogen's Tecfidera and Vumerity have faced competition from other oral multiple sclerosis treatments, even where direct generic substitution has been slower.
Japan
Japan has a distinct regulatory and reimbursement environment. Approval timing, local clinical requirements and pricing revisions can delay the effects of global patent expiry.
Emerging markets
Generic manufacturers can compete aggressively in markets with less restrictive reimbursement systems. Local manufacturing, registration requirements and price controls determine access and margin.
The key international trend is declining branded price power rather than immediate volume collapse. Tecfidera can retain revenue in markets where substitution is restricted, but global average price is likely to continue falling.
What licensing deals affect the dimethyl fumarate market?
The commercial history of dimethyl fumarate has been driven more by internal lifecycle management and generic litigation than by major third-party licensing transactions.
Biogen developed Tecfidera and Vumerity as part of its own multiple sclerosis franchise. The most material strategic transaction relevant to the broader franchise was Biogen's acquisition of Reata Pharmaceuticals in 2023, which expanded its portfolio beyond fumarates but did not change the basic patent or generic economics of dimethyl fumarate (Biogen, 2023).
Generic manufacturers generally rely on ANDA development and supply arrangements rather than high-value licenses from Biogen. Any settlement agreement between Biogen and an individual ANDA sponsor would be applicant-specific and could affect entry timing without restoring a broad market monopoly.
How strong is the dimethyl fumarate patent estate?
The patent estate is moderate to weak for legacy dimethyl fumarate and stronger for selected follow-on products.
| Assessment area |
Rating |
Analysis |
| Active-ingredient protection |
Weak |
Known small molecule with limited late-life composition protection |
| Dosing patents |
Weak to moderate |
Vulnerable where dose selection is predictable from prior art |
| Delayed-release formulation |
Moderate |
Can support product differentiation but may be design-aroundable |
| Manufacturing patents |
Moderate |
Useful for quality and process control, less effective as a broad market barrier |
| Vumerity product patents |
Stronger than Tecfidera's legacy estate |
Separate prodrug and formulation claims create a longer runway |
| Litigation durability |
Limited for Tecfidera |
Key patent invalidation enabled early generic entry |
| Generic launch exposure |
High |
Multiple ANDA sponsors and established substitution economics |
The decisive weakness was dependence on secondary patent claims to protect a blockbuster whose active ingredient was already known. The patent estate could support litigation, but it did not sustain exclusivity after the core dosing patent failed.
What generic launch scenarios remain?
The most likely commercial scenario is continued erosion of Tecfidera revenue, with generic dimethyl fumarate maintaining a large share of price-sensitive prescriptions.
Base case
Generic suppliers maintain broad access, and Tecfidera becomes a residual branded product. Vumerity retains a smaller branded niche based on tolerability and patient persistence.
Downside case for Biogen
Additional generic entrants intensify price competition, payers restrict Vumerity coverage, and patients switch directly from Tecfidera to low-cost generic dimethyl fumarate or competing oral therapies.
Upside case for Biogen
Vumerity demonstrates enough tolerability and adherence value to preserve premium reimbursement, while Tecfidera maintains a stable international base in markets with limited substitution.
The base case favors declining Tecfidera sales, moderate persistence for Vumerity and continued migration of value from the originator to generic manufacturers and payers.
What is the revenue exposure for Biogen and generic manufacturers?
Tecfidera remains financially relevant but is no longer the growth engine it was before 2020. Its exposure is concentrated in:
- U.S. residual branded sales.
- International markets with delayed generic penetration.
- Existing patients who remain stable on therapy.
- Net pricing after rebates and discounts.
For generic manufacturers, the market offers volume but limited long-term pricing power. The product has a large treated population and established prescribing patterns, yet several suppliers can produce comparable products. Margins will depend on launch sequence, manufacturing cost, payer contracts and supply reliability.
Vumerity gives Biogen a higher-value branded exposure than genericized Tecfidera, but the product faces a narrower addressable market and must defend a price premium. The overall fumarate franchise is therefore transitioning from a blockbuster model to a portfolio-management model.
Key Takeaways
- Dimethyl fumarate is a mature oral multiple sclerosis market with high generic-entry exposure.
- Tecfidera peaked at approximately $4.4 billion in 2019 before U.S. generic competition.
- Revenue declined sharply after the invalidation of U.S. Patent No. 8,399,514 and generic launches in 2020.
- FDA NCE exclusivity ended in 2018; patent litigation determined the practical timing of generic entry.
- Generic dimethyl fumarate, not biosimilars, is the relevant competitive pathway.
- Delayed-release formulation and manufacturing patents provide narrower protection than a composition-of-matter patent.
- Vumerity is Biogen's principal lifecycle-management product and relies on tolerability differentiation and its separate patent estate.
- Therapeutic substitution from oral agents to high-efficacy biologics is a larger long-term market risk than generic price competition alone.
- Tecfidera revenue should continue to decline, while Vumerity is likely to retain a smaller branded role if reimbursement supports its tolerability proposition.
FAQs
Is dimethyl fumarate still a blockbuster drug?
The active ingredient remains commercially important, but branded Tecfidera is no longer a blockbuster at its pre-generic revenue level. The broader dimethyl fumarate market remains substantial because of generic volume.
Can generic dimethyl fumarate replace Tecfidera automatically?
In many U.S. settings, an FDA-approved generic may be substituted subject to state pharmacy law and payer rules. Prescriber authorization, product availability and formulary policy can affect substitution.
Does Vumerity have the same active metabolite as Tecfidera?
Yes. Diroximel fumarate converts to monomethyl fumarate, the same principal active metabolite generated by dimethyl fumarate.
Is dimethyl fumarate protected by orphan-drug exclusivity?
No. Multiple sclerosis is not an orphan indication for dimethyl fumarate, and the product's principal U.S. protections arose from NCE exclusivity and patents rather than orphan-drug exclusivity.
What is the main investment risk in the dimethyl fumarate market?
The main risk is continued loss of branded pricing power through generic substitution, payer pressure and switching to competing oral or high-efficacy multiple sclerosis therapies.
References
-
Biogen Inc. (2020). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2019. U.S. Securities and Exchange Commission.
-
Biogen Inc. (2021). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2020. U.S. Securities and Exchange Commission.
-
Biogen Inc. (2022). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2021. U.S. Securities and Exchange Commission.
-
Biogen Inc. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2022. U.S. Securities and Exchange Commission.
-
Biogen Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2013). FDA approves new multiple sclerosis treatment. FDA.
-
U.S. Food and Drug Administration. (2024a). Drugs@FDA: Tecfidera prescribing information and regulatory exclusivity data. FDA.
-
U.S. Court of Appeals for the Federal Circuit. (2020). Biogen International GmbH v. Mylan Pharmaceuticals Inc., 18-1163.
-
U.S. Patent and Trademark Office. (2024). Patent Center and Orange Book-related patent records for dimethyl fumarate products. USPTO.
